Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
ir.vikingtherapeutics.com